Table 5 Characteristics of included studies for meta-analysis
Study | Stage | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) | ctDNA Method | tDNA Method | Targeted Gene |
|---|---|---|---|---|---|---|---|---|---|---|
Bin Zhang et al | early-stage | 15 | 5 | 25 | 3 | 0.38 (0.23–0.54) | 0.38 (0.09–0.76) | NGS | NGS | Panel Targeted 546 GENES* |
Charu Aggarwal et al | IV | 54 | 11 | 21 | 42 | 0.72 (0.60–0.82) | 0.79 (0.66–0.89) | NGS | NGS | Panel Targeted 73 GENES;153GENES* |
Chenglong Zhao et al | Advanced | 381 | 21 | 111 | 6 | 0.77 (0.73–0.81) | 0.22 (0.09–0.42) | NGS | NGS | Panel Targeted 168 GENES |
García-Pardo et al | Advanced | 35 | 5 | 1 | 28 | 0.97 (0.85–1.00) | 0.85 (0.68–0.95) | NGS | NGS | EGFR; ALK;ROS1;MET;ERBB2;BRAF;KRAS |
Hao Bai et al | I-IV | 20 | 11 | 6 | 42 | 0.77 (0.56–0.91) | 0.79 (0.66–0.89) | NGS | AMRS-PCR | EGFR |
Jian-xin Yin et al | IA-IV | 7 | 5 | 0 | 64 | 1.00 (0.59–1.00) | 0.93 (0.84–0.98) | NGS | NGS | EGFR; KRAS |
Jun Cai et al | Advanced | 30 | 3 | 16 | 0 | 0.65 (0.50–0.79) | 0.00 (0.00–0.71) | NGS | NGS | Panel Targeted 95 GENES* |
Justin Jee et al | Advanced | 216 | 3 | 163 | 538 | 0.57 (0.52–0.62) | 0.99 (0.98–1.00) | NGS | NGS | Panel Targeted 24GENES* |
Lawrence Hsu Lin et al | II- IV | 27 | 3 | 23 | 18 | 0.54 (0.39–0.68) | 0.86 (0.64–0.97) | NGS | NGS | Panel Targeted 74 GENES* |
Luis E. Raez et al | IV | 14 | 18 | 7 | 114 | 0.67 (0.43–0.85) | 0.86 (0.79–0.92) | NGS | NGS | Panel Targeted 86 GENES* |
Maria Gabriela O. et al | II IV | 51 | 3 | 12 | 61 | 0.81 (0.69–0.90) | 0.95 (0.87–0.99) | NGS | NGS | Panel Targeted 24 GENES* |
Martin Metzenmacher et al | IV | 10 | 3 | 3 | 0 | 0.77 (0.46–0.95) | 0.00 (0.00–0.71) | NGS | NGS | Panel Targeted 73 GENES* |
Moom R. et al | I-IV | 89 | 66 | 62 | 3 | 0.59 (0.51–0.67) | 0.04 (0.00–0.12) | NGS | NGS | ALK,EGFR,ROS1,BRAF,RET,MET, ERBB2, KRAS |
Paul van et al | Advanced | 33 | 4 | 17 | 12 | 0.66 (0.51–0.79) | 0.75 (0.48–0.93) | NGS | NGS | EGFR, KRAS, BRAF, ERBB2, and PIK3CA |
Peng-Peng Kuang et al | IB-III | 19 | 0 | 19 | 0 | 0.50 (0.33–0.67) | Not estimable | NGS | NGS | Panel Targeted 425 GENES* |
Ramon Palmero et al | Advanced | 29 | 17 | 19 | 3 | 0.60 (0.45–0.74) | 0.15 (0.03–0.38) | NGS | NGS | ALK,EGFR,ROS1,BRAF,RET, MET, ERBB2, KRAS |
Sehhoon Park et al | Advanced | 108 | 11 | 53 | 87 | 0.67 (0.59–0.74) | 0.89 (0.81–0.94) | NGS | NGS | Panel Targeted 74 GENES* |
Sheehyun Kim et al | Advanced | 28 | 18 | 19 | 0 | 0.60 (0.44–0.74) | 0.00 (0.00–0.19) | NGS | NGS | Panel Targeted 171 and 25 fusion genes* |
Vassiliki A. et al | Advanced | 566 | 53 | 287 | 754 | 0.66 (0.63–0.70) | 0.93 (0.91–0.95) | NGS | PCR | EGFR |
Yukti Choudhury et al | I-IV | 9 | 2 | 3 | 10 | 0.75 (0.43–0.95) | 0.83 (0.52–0.98) | NGS | NGS | Panel Targeted 49 GENES* |
Zeyun Lin et al | I-IV | 81 | 6 | 34 | 69 | 0.70 (0.61–0.79) | 0.92 (0.83–0.97) | NGS | NGS | Panel Targeted 168 GENES* |